Bavarian Nordic, WHO and Mpox
WHO Approves Bavarian Nordic's Mpox Vaccine for Adolescents
The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the disease that has triggered global concern.
City of El Paso confirms 2 cases of Mpox
The World Health Organisation (WHO) defines Mpox as an acute viral illness with fever, headache, lymph node enlargement, back ...
And the community most affected by mpox is one that has suffered multiple other outbreaks—most notably, the HIV/AIDS crisis.
Bavarian Nordic’s mpox vaccine Jynneos generated a similar immune response in adolescents as it did in adults, offering ...
The world “cannot be complacent” about the threat posed by mpox, Anneliese Dodds has warned, as the UK unveiled up to £9 ...
A clinical trial of an mpox vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults, according to a planned interim analysis of study data.
Missteps by the World Health Organization, a vaccine manufacturer and an African country led to another health emergency, ...
U.S. health officials have identified a cluster of cases caused by an mpox variant that are resistant to Siga Technologies' ...
The City of El Paso's Department of Public Health (DPH) just confirmed two Mpox cases. The two infected people are described as men in their 40s who live in the same house. They are both recovering at ...
A National Institutes of Health (NIH)-funded clinical trial of an mpox vaccine in adolescents found it was safe and generated ...
A delayed reaction by public health officials to the virus in 2022 led to misinformation, panic and an initial lack of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback